SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

August 20, 2013 12:04 ET

Elsevier Business Intelligence (EBI) to Host the '23rd Annual PSA: The Pharmaceutical Strategy Conference,' September 23-25, 2013, Millennium Broadway Hotel (New York)

Focus Is 'Rebooting Growth: Maximizing the Value of Scientific and Business Model Innovation;' Attracts 200-300 Top Industry Executives; Tadataka "Tachi" Yamada to Key Note, Accompanied by Senior Executives From Biogen, Merck, Regeneron, Pfizer, AstraZeneca, and Other Biotechs and Pharma Companies and Investors

BEDMINSTER, NJ--(Marketwired - Aug 20, 2013) - As the pharmaceutical industry strives to overcome many of today's challenges -- from siloed organizations to bureaucracy and inefficient decision-making -- pharmaceutical companies face ever-changing, complex and costly models of research and development. The lessons that industry is learning as it forges new relationships and engages in emerging markets and developing countries provide unique insights that can be leveraged to help overcome these challenges, according to Tachi Yamada, M.D., head of R&D for Takeda Pharmaceutical, Japan's largest drug company.

Dr. Yamada, who has been the chief medical and scientific officer and member of the Board of Takeda since 2011, will speak on September 24 at Elsevier Business Intelligence's annual "PSA: The Pharmaceutical Strategy Conference," in New York City about the opportunity to leverage these learning's to guide the pharmaceutical industry through the ongoing evolution of its complex, science-based global R&D model.

PSA, now in its 23rd year, is the biopharma industry's best-known and most forward-thinking annual gathering of top industry executives. This year's conference focuses on maximizing scientific and business model innovation in order to jumpstart corporate growth. Executives in R&D, business development, and commercial activities will discuss how the industry is responding to new hurdles to produce meaningful innovation. With the U.S. now fully immersed in implementing health care reform and facing increasing cost-containment challenges in key markets abroad, biopharma must adapt to pressures from its core customers, who face challenges of their own. 

Dr. Yamada is uniquely able to speak to large-scale R&D transformation, based on his past experiences as president of Global Health Program at the Bill & Melinda Gates Foundation and as head of R&D and member of the board of GlaxoSmithKline, where he drove a seismic shift from highly centralized R&D organization into smaller, more nimble units. He currently is leading Takeda R&D through significant transformation, increasing productivity and development of one of the industry's richest and deepest pipelines following the loss of exclusivity for Actos, Takeda's blockbuster type 2 diabetes treatment.

In addition to Dr. Yamada, his colleague Anna Protopapas, president of Millennium: The Takeda Oncology Company and head of Takeda's global business development, will talk about how the most up-to-date, deal-making trends are affecting broad corporate strategy and vice versa. Anna drives partnerships for Takeda that aim to generate revenue and significant value for the organization.

Other R&D, business development, and commercial leaders also will be at PSA to discuss how they are managing their organizations through seismic transformation and next-steps in scientific and organizational evolution. These include Rupert Vessey, SVP, Global Scientific Strategy at Merck; and George Yancopoulos, President of Regeneron Laboratories. Vessey has held numerous leadership positions within Merck R&D, most recently as head of Merck Research Labs' respiratory and immunology pipeline before assuming his current position, which gives him broad responsibilities across franchise areas. Yancopoulos, who also holds the title of CSO at Regeneron, led the discovery and development of the biotech's phenomenally successful first product, the ophthalmic drug Eylea, which is expected to surpass $1 billion in sales this year, its second on the market. Regeneron currently has a full slate of mid-to-late stage products, some expected to be up for regulatory review in 2014 and 2015.

Fran Heller, who joined Bristol-Myers Squibb (BMS) as SVP, Business Development, in 2012, will discuss her business development priorities in relationship to the company's overall corporate strategy. Prior to joining BMS, Ms. Heller was EVP, Business Development, at the cancer biotech Exelixis.

At PSA, not only will the industry's key executives share lessons learned and practical advice for sealing a deal, but these opinion leaders also will debate top-of-mind issues -- from enhancing R&D productivity, to executing a commercial launch strategy.

Attendees will gain:

  • The Best Networking in the Business;
  • Case Studies on forging new relationships with stakeholders;
  • Strategies for Mitigating Deal Risks;
  • Strategies for Optimizing The Value Of Drugs In A New Commercial Landscape;
  • Accessing Innovation to Fuel Sustainable Growth;
  • Benchmark R&D/BD Business Models against the Best, the Brightest and Competitors.

PSA is the only meeting to gather in one place the industry's top thinkers to explain solutions to the fundamental challenges facing biotech and pharma.

"PSA: Pharmaceutical Strategic Alliances is a rare opportunity to provide a discussion of the various, most promising proposed solutions to the industry's toughest challenges," said Chris Morrison, Editor-in-Chief, Biopharmaceuticals and Consumer Products at Elsevier Business Intelligence.

Other speakers at PSA are:

  • JC Gutierrez-Ramos, SVP and Head of Biotherapeutics R&D, Pfizer
  • Imran Eba, Director, WW Business Development, GlaxoSmithKline
  • Donna Altenpohl, VP, Public Policy, GlaxoSmithKline
  • Percival Barretto-Ko, Senior Vice President, Corporate Strategy & Government Affairs, Astellas Pharma
  • Richard Francis, SVP, US Commercial, Biogen Idec
  • Johan L. Hoegstedt, Vice President, Managed Markets, AstraZeneca
  • Sven Borho, Partner, OrbiMed
  • Rajeev Shah, Partner, RA Capital Management
  • Tom M. Brakel, Senior Portfolio Manager, Federated Kaufmann
  • Robert Hodgson, Founder and Portfolio Manager, Lenus Capital Partners, LLC
  • Francois Nader, MD, CEO and President, NPS Pharmaceuticals Inc.
  • Paul Billings, Chief Medical Officer, Life Technologies
  • Rowan Chapman, Head of Precision Diagnostics, GE Healthcare
  • John Maraganore, CEO, Alnylam
  • Gregory Simon, CEO, Poliwogg
  • Martin Shkreli, CEO, Retrophin
  • Noubar Afeyan, CEO, Flagship Ventures
  • Peter Hecht, CEO, Ironwood Pharmaceuticals 
  • Friedhelm Blobel, PhD, President, Chief Executive Officer, SciClone
  • And many more...

To learn more about panel topics and keynote talks, visit:

About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and finance and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit

Contact Information

  • Media Contact:
    Mike Fergus
    Elsevier Business Intelligence
    +1 908 748 1185
    Email Contact